Rapport Therapeutics, Inc. Common Stock (RAPP) is a Healthcare · Biotechnology company listed on NASDAQ. Price $40.85 (-2.62%), Market cap $1.76B, 52-week low–high $8.27 ~ $39.93.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the tr
Financial statements, price targets, institutional (13F) holdings and related news for Rapport Therapeutics, Inc. Common Stock are updated in real time on BlackAll Trade.
Rapport Therapeutics, Inc. Common Stock trades at $40.85 (-2.62%). Real-time quotes and charts are available on BlackAll Trade.
Rapport Therapeutics, Inc. Common Stock has a market cap of about $1.76B.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering fro